Horizon Therapeutics plc

If you purchased Horizon Therapeutics plc securities and would like to join the action, please click "Join This Action" below.

HZNP STOCK ALERT: HALPER SADEH LLC IS INVESTIGATING WHETHER THE SALE OF HORIZON THERAPEUTICS PLC IS FAIR TO SHAREHOLDERS

December 12, 2022.

New York, New York—Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Horizon Therapeutics plc (NASDAQ: HZNP) to Amgen Inc. for $116.50 in cash per share is fair to Horizon shareholders.

The investigation concerns whether Horizon and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Horizon shareholders; (2) determine whether Amgen is underpaying for Horizon; and (3) disclose all material information necessary for Horizon shareholders to adequately assess and value the merger consideration. On behalf of Horizon shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Scroll to Top